RVMD
Income statement / Annual
Last year (2025), Revolution Medicines Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Revolution Medicines Inc's net income was -$1.13 B.
See Revolution Medicines Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$11.58 M |
$35.38 M |
$29.39 M |
$42.98 M |
$50.04 M |
$20.17 M |
$0.00 |
| Cost of Revenue |
$16.56 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$26.59 M
|
| Gross Profit |
-$16.56 M
|
$0.00
|
$11.58 M
|
$35.38 M
|
$29.39 M
|
$42.98 M
|
$50.04 M
|
$20.17 M
|
-$26.59 M
|
| Gross Profit Ratio |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
| Research and Development Expenses |
$978.68 M
|
$592.23 M
|
$423.14 M
|
$253.07 M
|
$186.95 M
|
$132.25 M
|
$91.76 M
|
$51.08 M
|
$26.59 M
|
| General & Administrative Expenses |
$187.13 M
|
$97.30 M
|
$75.62 M
|
$40.59 M
|
$30.45 M
|
$21.43 M
|
$12.41 M
|
$9.41 M
|
$4.54 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$187.13 M
|
$97.30 M
|
$75.62 M
|
$40.59 M
|
$30.45 M
|
$21.43 M
|
$12.41 M
|
$9.41 M
|
$4.54 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$26.59 M
|
| Operating Expenses |
$1.17 B
|
$689.52 M
|
$498.77 M
|
$293.66 M
|
$217.40 M
|
$153.68 M
|
$104.16 M
|
$60.49 M
|
$4.54 M
|
| Cost And Expenses |
$1.18 B
|
$689.52 M
|
$498.77 M
|
$293.66 M
|
$217.40 M
|
$153.68 M
|
$104.16 M
|
$60.49 M
|
$31.13 M
|
| Interest Income |
$90.69 M
|
$86.88 M
|
$47.48 M
|
$9.15 M
|
$929.00 K
|
$2.24 M
|
$2.19 M
|
$777.00 K
|
$105.00 K
|
| Interest Expense |
$24.23 M
|
$0.00
|
$303.00 K
|
$0.00
|
$12.00 K
|
$71.00 K
|
$106.00 K
|
$116.00 K
|
$103.00 K
|
| Depreciation & Amortization |
$16.56 M
|
$11.82 M
|
$9.31 M
|
$9.66 M
|
$7.33 M
|
$6.55 M
|
$3.34 M
|
$1.76 M
|
$1.19 M
|
| EBITDA |
-$1.09 B |
-$677.70 M |
-$477.88 M |
-$248.62 M |
-$179.75 M |
-$101.91 M |
-$48.59 M |
-$39.91 M |
-$29.84 M |
| EBITDA Ratio |
0
|
0
|
-41.27
|
-7.03
|
-6.12
|
-2.37
|
-0.97
|
-1.98
|
0
|
| Operating Income Ratio |
0
|
0
|
-42.07
|
-7.3
|
-6.4
|
-2.58
|
-1.08
|
-2
|
0
|
| Total Other Income/Expenses Net |
$51.07 M
|
$88.68 M
|
$47.29 M
|
$9.15 M
|
$917.00 K
|
$2.17 M
|
$2.08 M
|
-$1.46 M
|
$2.00 K
|
| Income Before Tax |
-$1.13 B
|
-$600.85 M
|
-$439.89 M
|
-$249.13 M
|
-$187.09 M
|
-$108.53 M
|
-$52.04 M
|
-$41.79 M
|
-$31.13 M
|
| Income Before Tax Ratio |
0
|
0
|
-37.99
|
-7.04
|
-6.37
|
-2.52
|
-1.04
|
-2.07
|
0
|
| Income Tax Expense |
$0.00
|
-$753.00 K
|
-$3.52 M
|
-$420.00 K
|
$0.00
|
-$371.00 K
|
-$4.37 M
|
$0.00
|
$105.00 K
|
| Net Income |
-$1.13 B
|
-$600.09 M
|
-$436.37 M
|
-$248.71 M
|
-$187.09 M
|
-$108.16 M
|
-$47.66 M
|
-$41.79 M
|
-$31.13 M
|
| Net Income Ratio |
0
|
0
|
-37.68
|
-7.03
|
-6.37
|
-2.52
|
-0.95
|
-2.07
|
0
|
| EPS |
-5.95 |
-3.58 |
-3.86 |
-3.08 |
-2.47 |
-1.62 |
-1.31 |
-1.15 |
-0.85 |
| EPS Diluted |
-5.95 |
-3.58 |
-3.86 |
-3.08 |
-2.47 |
-1.62 |
-1.31 |
-1.15 |
-0.85 |
| Weighted Average Shares Out |
$190.13 M
|
$167.74 M
|
$113.15 M
|
$80.63 M
|
$72.81 M
|
$66.60 M
|
$36.47 M
|
$36.47 M
|
$36.47 M
|
| Weighted Average Shares Out Diluted |
$190.13 M
|
$167.74 M
|
$113.15 M
|
$80.63 M
|
$72.81 M
|
$66.60 M
|
$36.47 M
|
$36.47 M
|
$36.47 M
|
| Link |
|
|
|
|
|
|
|
|
|
